Related Experiment Video
Updated: Apr 6, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Cardiovascular pharmacotherapy in 2025
Juan Tamargo1, Stefan Agewall2,3, Giuseppe Ambrosio4,5
1Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, Avenida Ramón y Cajal s/n, Madrid 29040, Spain.
None:
Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiomyopathy V: Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Heart Failure V: Medical Management

